Phio Pharmaceuticals (PHIO) EBITDA (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly EBITDA came in at -$4.2 million in Q1 2026, down 122.6% YoY from $18.4 million in Q1 2025, and down 66.35% on a QoQ basis from -$2.5 million in Q3 2025.
Phio Pharmaceuticals (PHIO) EBITDA (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of EBITDA data on file, last reported at -$4.2 million in Q1 2026.
- Quarterly EBITDA fell 122.6% year-over-year to -$4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.9 million (down 53.94% YoY) and the FY2024 annual result came in at -$7.4 million, up 31.75% from the prior year.
- EBITDA declined to -$4.2 million in Q1 2026, from -$2.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$1.6 million in Q3 2024 to a low of -$4.2 million in Q1 2026.
- A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA soared 42.72% — and 2026, when it plunged 122.6%.
- Tracing PHIO's EBITDA over 5 years: stood at -$2.7 million in 2022, then surged by 30.44% to -$1.9 million in 2023, then advanced by 11.85% to -$1.7 million in 2024, then plunged by 49.64% to -$2.5 million in 2025, then plunged by 66.35% to -$4.2 million in 2026.
- The last three EBITDA figures came in at -$4.2 million (Q1 2026), -$2.5 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | -4.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.27 Mn |
| Mar 31, 2026 | -4.17 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | -2.31 Mn |
| Mar 31, 2025 | -1.87 Mn |
| Dec 31, 2024 | -1.67 Mn |
| Sep 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -1.91 Mn |
| Mar 31, 2024 | -2.21 Mn |
| Dec 31, 2023 | -1.90 Mn |
| Sep 30, 2023 | -2.78 Mn |
| Jun 30, 2023 | -2.55 Mn |
| Mar 31, 2023 | -3.60 Mn |
| Dec 31, 2022 | -2.73 Mn |
| Sep 30, 2022 | -3.57 Mn |
| Jun 30, 2022 | -2.52 Mn |
| Mar 31, 2022 | -2.64 Mn |
| Dec 31, 2021 | -3.45 Mn |
| Sep 30, 2021 | -3.74 Mn |
| Jun 30, 2021 | -2.68 Mn |